» Articles » PMID: 33752798

Convalescent COVID-19 Patients Are Susceptible to Endothelial Dysfunction Due to Persistent Immune Activation

Abstract

Numerous reports of vascular events after an initial recovery from COVID-19 form our impetus to investigate the impact of COVID-19 on vascular health of recovered patients. We found elevated levels of circulating endothelial cells (CECs), a biomarker of vascular injury, in COVID-19 convalescents compared to healthy controls. In particular, those with pre-existing conditions (e.g., hypertension, diabetes) had more pronounced endothelial activation hallmarks than non-COVID-19 patients with matched cardiovascular risk. Several proinflammatory and activated T lymphocyte-associated cytokines sustained from acute infection to recovery phase, which correlated positively with CEC measures, implicating cytokine-driven endothelial dysfunction. Notably, we found higher frequency of effector T cells in our COVID-19 convalescents compared to healthy controls. The activation markers detected on CECs mapped to counter receptors found primarily on cytotoxic CD8 T cells, raising the possibility of cytotoxic effector cells targeting activated endothelial cells. Clinical trials in preventive therapy for post-COVID-19 vascular complications may be needed.

Citing Articles

Cardiovascular Symposium on Perspectives in Long COVID.

Dieter R, Kempaiah P, Dieter E, Alcazar A, Tafur A, Gerotziafas G Clin Appl Thromb Hemost. 2025; 31:10760296251319963.

PMID: 39943820 PMC: 11822813. DOI: 10.1177/10760296251319963.


Medium- to long-term health condition of patients post-COVID-19, exercise intolerance and potential mechanisms: A narrative review and perspective.

Schwendinger F, Infanger D, Maurer D, Radtke T, Carrard J, Kropfl J SAGE Open Med. 2025; 12:20503121241296701.

PMID: 39902344 PMC: 11789121. DOI: 10.1177/20503121241296701.


Potential Biomarkers for Predicting the Risk of Developing Into Long COVID After COVID-19 Infection.

Hou Z, Ming Y, Liu J, Wang Z Immun Inflamm Dis. 2025; 13(1):e70137.

PMID: 39853911 PMC: 11760981. DOI: 10.1002/iid3.70137.


Treatment with Sulodexide Downregulates Biomarkers for Endothelial Dysfunction in Convalescent COVID-19 Patients.

Gonzalez-Ochoa A, Szolnoky G, Hernandez-Ibarra A, Fareed J Clin Appl Thromb Hemost. 2025; 31():10760296241297647.

PMID: 39763448 PMC: 11705351. DOI: 10.1177/10760296241297647.


Sustained Vascular Inflammatory Effects of SARS-CoV-2 Spike Protein on Human Endothelial Cells.

Gultom M, Lin L, Brandt C, Milusev A, Despont A, Shaw J Inflammation. 2024; .

PMID: 39739157 DOI: 10.1007/s10753-024-02208-x.


References
1.
Apostolakis S, Vogiatzi K, Amanatidou V, Spandidos D . Interleukin 8 and cardiovascular disease. Cardiovasc Res. 2009; 84(3):353-60. DOI: 10.1093/cvr/cvp241. View

2.
Bodnar R, Yates C, Wells A . IP-10 blocks vascular endothelial growth factor-induced endothelial cell motility and tube formation via inhibition of calpain. Circ Res. 2006; 98(5):617-25. PMC: 3826264. DOI: 10.1161/01.RES.0000209968.66606.10. View

3.
Yu H, Lee H, Choi H, Ahn J, Choi J, Song H . Characterization of CD45-/CD31+/CD105+ circulating cells in the peripheral blood of patients with gynecologic malignancies. Clin Cancer Res. 2013; 19(19):5340-50. DOI: 10.1158/1078-0432.CCR-12-3685. View

4.
Young B, Fong S, Chan Y, Mak T, Ang L, Anderson D . Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study. Lancet. 2020; 396(10251):603-611. PMC: 7434477. DOI: 10.1016/S0140-6736(20)31757-8. View

5.
Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, de Mol M . Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 2001; 7(5):575-83. DOI: 10.1038/87904. View